This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Researchers in Australia have created an innovative drug delivery system that utilises a metalbiomolecule network (MBN) comprising of non-toxic metal ions together with phosphonate biomolecules, eg, DNA. As the MBN nanoparticles do not require complicated drug carriers and the materials are bio-compatible, the system has potential to boost successful drug development, according to first author Dr Wanjun Xu.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Democratic lawmakers are calling for aggressive action to curb the increasing market power of UnitedHealth Group, including a possible breakup of a business empire they say is undermining competition, corrupting Medicare, and hurting vulnerable patients. The lawmakers, including several U.S. senators, argue the problems created by the company’s size and reach demand immediate steps to restore public confidence in the health care system.
By aligning the pharmacy revenue cycle with the 340B Drug Pricing Program, organizations can maximize revenue capture from medications while ensuring compliance with 340B requirements, leading to enhanced financial performance and improved care for underserved populations.
A conversation with Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, professor of pharmacy practice at Massachusetts College of Pharmacy and Health Sciences.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacists are essential in preventing the significant health and economic burden of respiratory syncytial virus (RSV) infections in older adults through vaccination.
WASHINGTON — Three large pharmaceutical companies left the brand-drug lobby PhRMA after the passage of Democrats’ drug pricing law in 2022. Following the exits, the organization collected $100 million less in annual membership dues, new tax filings show.
A study in Lancet Haematology revealed that minority ethnic patients face significantly poorer outcomes after hematopoietic cell transplantation compared to White patients.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
State lawmakers are fed up with federal inaction on artificial intelligence and are taking matters into their own hands. Lawmakers in Colorado, California, and Connecticut this year managed to pass AI-related bills, some quite sweeping in nature, even if the more ambitious ones were eventually killed by governors. And it’s not just blue states trying to fit guardrails onto the fast-moving AI industry.
Stay updated on the latest Good Manufacturing Practices (GMP) and quality compliance standards in the digital era with our comprehensive guide. Learn how to ensure your products meet regulatory requirements.
Lillys Zepbound has become the first prescription medicine approved to treat adults with moderate to severe obstructive sleep apnoea (OSA) and obesity.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Learn how compounding pharmacies ensure safety and reliability through rigorous standards, sterile preparations, and personalized solutions for unique healthcare needs. The post Are Compounding Pharmacies Safe? Everything You Need to Know appeared first on Compounding Pharmacy of America.
Despite significant headwinds coming to bear over the past several years, healthcare executives are expecting a favorable 2025, according to a new survey from Deloitte.
The past year has been a complicated one for health insurers, and our top stories of the year reflect the headwinds many companies faced and represent two unprecedented events that shook the industry.
Currently available for prescription in the United States, vibegron is now the first and only 3 agonist FDA approved to treat patients living with OAB and being treated for BPH.
AI and software company Commure has acquired Memora Health, a digital care navigation platform launched out of the Harvard Innovation Labs. | Health tech company Commure has acquired Memora Health, a Harvard Innovation Labs company backed by General Catalyst.
Medicare Advantage, UnitedHealth Group, physician pay and reimbursement and layoffs were top of mind for Fierce Healthcare readers in 2024. Major changes in the primary care and telehealth markets also drew readers' interest this past year.
Short-term spinal cord stimulation could provide long-term pain relief and improve the overall quality of life for individuals with herpes zoster-associated pain and postherpetic neuralgia.
Pharmacists can optimize IVIG treatment for BK nephropathy in kidney transplant recipients by educating providers and monitoring for infusion reactions.
The 2025 GOLD Report emphasizes the importance of tailoring combination treatments based on patient factors like eosinophil counts and exacerbation history.
65
65
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content